Evidence map›Paper›PMID 26846539›Full record

ArticleCardiovascular diabetology2016

Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region.

Ildiko Toma, Paul J Kim, Rajesh Dash, Michael V McConnell, Dwight Nishimura, Phillip Harnish, Phillip C Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ildiko TomaDepartment of Medicine, Stanford University, Stanford, CA, USA. ildikotoma@gmail.com.
Paul J KimDepartment of Medicine, Stanford University, Stanford, CA, USA. pjkim08@stanford.edu.
Rajesh DashDepartment of Medicine, Stanford University, Stanford, CA, USA. phillip@stanford.edu.
Michael V McConnellDepartment of Medicine, Stanford University, Stanford, CA, USA. mvm@stanford.edu.
Dwight NishimuraDepartment of Electrical Engineering, Stanford University, Stanford, CA, USA. dwight@stanford.edu.
Phillip HarnishEagle Vision Pharmaceutical Corporation, Downingtown, PA, USA. eaglevpc2@aol.com.
Phillip C YangDepartment of Medicine, Stanford University, Stanford, CA, USA. phillip@stanford.edu.
Stanford University · USEagle Pharmaceuticals (United States) · USStanford Medicine · US

Funding

Multi-Disciplinary Training Program in Cardiovascular Imaging at StanfordT32EB009035 · NIBIB · STANFORD UNIVERSITY · PI Koen Nieman, John M. Pauly · 2008 to 2026
$4.3M
6 · The paper itself

Abstract

backgroundA novel MRI technique, employing dual contrast manganese-enhanced MRI (MEMRI) and delayed enhancement MRI (DEMRI), can evaluate the physiologically unstable peri-infarct region. Dual contrast MEMRI-DEMRI enables comprehensive evaluation of telmisartan to salvage the peri-infarct injury to elucidate the underlying mechanism of restoring the ischemic cardiomyopathy in the diabetic mouse model. METHODS AND

resultsDual contrast MEMRI-DEMRI was performed on weeks 1, 2, and 4 following initiation of telmisartan treatment in 24 left anterior descendent artery ligated diabetic mice. The MRI images were analyzed for core infarct, peri-infarct, left ventricular end-diastolic, end-systolic volumes, and the left ventricular ejection fraction (LVEF). Transmission electron microscopy (TEM) and real-time PCR were used for ex vivo analysis of the myocardium. Telmisartan vs. control groups demonstrated significantly improved LVEF at weeks 1, 2, and 4, respectively (33 ± 7 %*** vs. 19 ± 5 %, 29 ± 3 %*** vs. 22 ± 4 %, and 31 ± 2 %*** vs 18 ± 6 %, ***p < 0.001). The control group demonstrated significant differences in the scar volume measured by MEMRI and DEMRI, demonstrating peri-infarct injury. Telmisartan group significantly salvaged the peri-infarct injury. The myocardial effects were validated by TEM, which confirmed the presence of the injured but viable cardiomyocyte morphology in the peri-infarct region and by flow cytometry of venous blood, which demonstrated significantly increased circulating endothelial progenitor cells (EPCs).

conclusionThe improved cardiac function in ischemic cardiomyopathy of diabetic mice by telmisartan is attributed to the attenuation of the peri-infarct injury by the angiogenic effects of EPCs to salvage the injured cardiomyocytes. Dual-contrast MEMRI-DEMRI technique tracked the therapeutic effects of telmisartan on the injured myocardium longitudinally.

Indexed as

Angiotensin II Type 1 Receptor BlockersAnimalsApoptosisBenzimidazolesBenzoatesContrast MediaDiabetes Mellitus, Type 2Disease Models, AnimalEndothelial Progenitor CellsFibrosisFlow CytometryGadolinium DTPAMagnetic Resonance ImagingManganeseMice, Inbred C57BLMice, TransgenicAngiotensin II Type 1 Receptor BlockersBenzimidazolesBenzoatesContrast MediaEVP 1001-1Gadolinium DTPAManganeseTelmisartan

Identifiers

PMID26846539
PMCPMC4743104
OpenAlexW2252420734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.